Gene Combination of CD44 rs187116, CD133 rs2240688, NF-κB1 rs28362491 and GSTM1 Deletion as a Potential Biomarker in Risk Prediction of Breast Cancer in Lower Northern Thailand

Kamonpat Sapcharoen¹, Phanchana Sanguansermsri¹, Sukkid Yasothornsrikul¹, Kanha Muisuk², Metawee Srikummool¹,³*

Abstract

Background: Biomarkers play an important role in oncology, including risk assessment, treatment prediction, and monitoring the progression of disease. In breast cancer, many genes are used as biomarkers. Since, several SNP variations of hallmark-related genes have been reported to be of value in risk prediction in various cancers and populations, some genetic polymorphism loci were combined and reported as biomarkers for use in the risk assessment of breast cancer in Thai people. Methods: Twelve cancer gene hallmarks (15 polymorphic loci) were selected and genotyped in 184 breast cancer patients and 176 healthy individuals in Phitsanulok, Thailand. Results: AA genotype of CD44 rs187116 (c.67+4883G>A), the C allele of CD133 rs2240688 (c.*667A>C), the *2 allele (4 bp deletion) of NF-κB1 rs28362491 and the homozygous null allele genotype of GSTM1 were significantly associated with an increased risk of breast cancer (p<0.05). A combination of these 4 significant loci showed that AA-AA-*1*1-homozygous null allele genotype has the greatest correlation with increased risk of breast cancer (OR = 21.00; 95% CI: 1.77 to 248.11; p = 0.015), followed by GA-AA-*2*2- homozygous null allele genotype (p = 0.037) and GG-AC-*1*2- homozygous null allele genotype (p = 0.028). Conclusion: These findings suggest that the polymorphisms of CD44 rs187116 (c.67+4883G>A), CD133 rs2240688 (c.*667A>C), NF-κB1 rs28362491 and GSTM1 homozygous null allele genotype might be associated with an increased risk of breast cancer, and this gene combination could possibly be used as biomarkers for risk prediction, which would be of benefit in planning health surveillance and cancer prevention.

Keywords: Breast cancer- surveillance- genetic biomarker- polymorphism

Introduction

Breast cancer (BCA) is the most common form of cancer in women (Bray et al., 2018; NCI, 2017). Age, gender, estrogen, family history, gene mutation and unhealthy lifestyles are risk factors for this cancer (Sun et al., 2017). In 2011, Hanahan and Weinberg described the occurrence and progression of cancer, known as the hallmark of cancer (Hanahan and Weinberg, 2011). These include evading growth suppressors, avoiding immune destruction, enabling replicative immortality, tumor-promoting inflammation, activating invasion and metastasis, inducing angiogenesis, genome instability and mutation, resistance cell death, deregulating cellular energetics, and sustaining proliferative signaling (Hanahan and Weinberg, 2011). These characteristics result from an abnormality of regulatory genes, such as VEGF genes that induce angiogenesis (Hoeben et al., 2004; Carmeliet, 2005), or GSTM1, GSTT1, and NF-κB1 genes which induce the inflammation of tumor cells (Kim et al., 2006; Tang et al., 2010; Espın-Palazon and Traver, 2016). Other abnormalities in caspase 8 and caspase 9 genes could affect the death of cells (McIlwain et al., 2013); TGFβ, gene can induce cell multiplication via proliferative signaling (Villalobos et al., 2013); tumor suppressor gene (FOXO3) and proto-oncogene (MDM2) could induce cells to evade the growth suppressors (Essaghir et al., 2009; Urso et al., 2016). Cancer stem cells (CSCs) are a factor in cancer occurrence (Al-Hajj et al., 2003; Bozorgi et al., 2015). These cells were recognized as the key drivers of tumor development and progression, including tumor initiation, promotion, and metastasis which regulated cross-talks with tumor microenvironments in breast cancer (Ayob and Ramanamy, 2018; Feng et al., 2018). In order, to identify the CSCs, cell surface phenotypes such as CD24, CD44, CD90, CD117, CD133, should be checked (Schatton et
The molecules that might be used for predicting the occurrence of cancer, known as biomarkers, are DNA, mRNA, enzymes, metabolites, transcription factors, and cell surface receptors (Wu and Qu, 2015). Guidelines from the European Group on Tumor Markers (EGTM) reports that estrogen receptors (ERs), progesterone receptors (PRs), and human epidermal growth factor receptor 2 (HER2) are often used as breast cancer biomarkers (Duffy et al., 2017). The expression levels of ALDH1, CD24, CD44, and CD133 in breast cancer stem cells can also be used as biomarkers to detect solid tumors. (Jiang et al., 2012; Medema, 2013). The expression of these molecules almost always results from an abnormality in the genes. Mutations or polymorphisms in the gene sequences affected the cancer occurrence, progression, and susceptibility.

Single nucleotide polymorphisms (SNPs) and insertion-deletion polymorphisms (indel) have potential to indicate risk factors and susceptibility of lung, gastric, and breast cancer (Tan et al., 2010; Park et al., 2012; Eskandari-Nasab et al., 2016; Liu et al., 2016; Deng et al., 2017; Jia et al., 2017). For instance, the rs13347 (c.2392C>T) of CD44 was reported as a predictor marker for breast cancer risk and diagnosis (Jiang et al., 2012; Lin et al., 2018). Indel polymorphism of GSTM1 was found to be associated with breast cancer risk in Chinese and Mexican people (Soto-Quintana et al., 2015; Xue et al., 2016). However, GSTM1 genotypes were found to have no association with cancer susceptibility in Thai women (Pongtheerat et al., 2009).

The genetic background of populations play an important role in cancer risk and susceptibility, but there are no reports on the genetic variations in Thais. In this study, we selected 15 polymorphic loci from 12 genes relating to the hallmarks of cancer and cancer stem cell markers. We aimed to find candidate genes which are associated with breast cancer in Thai people from the lower Northern region and that could be used as biomarkers for breast cancer risk prediction, health surveillance, and cancer prevention planning.

Materials and Methods

Blood samples

Blood samples from 184 primary breast cancer patients and 176 healthy individuals, were collected by oncologists from Buddhachinaraj Phitsanulok Hospital, Phitsanulok, Thailand. Genomic DNA was isolated from whole blood by AccuPrep® Genomic DNA Extraction Kit (Bioneer, South Korea), according to the manufacturer’s protocol, and then the DNA concentration was measured by NanoDrop 2000 UV-Vis spectrophotometer (Thermo scientific, US). This project was approved by Naresuan University Research Ethics Committee No. 579/2017.

Genotyping

This study used several methods to analyze the genotypes. Polymerase chain reaction (PCR) was used for analyzing the genotypes of detoxification genes, GSTM1, and GSTT1. Each reaction contained DNA templates (2 – 5 ng/µl), 2X HS Taq Master Mix (Bioline, Canada), forward and reverse primers (Table 1), sterile water, and used the Albumin gene (ALB) as a positive internal control. MDM2 genotypes were analyzed by amplification refractory mutation system-polymerase chain reaction (ARMs–PCR). The DNA template (2 – 5 ng/µl), 2X HS Taq Master Mix (Bioline, Canada), 5 µM of each forward and reverse primers, and sterile water making up the total volume of 10 µl are contained in the reaction. For amplifying ALDH1, TGFβ2, caspase 8, caspase 9, NF-kB1, and VEGF, PCR with 6-FAM fluorescence dye labeled specific primers were used. The purified PCR products were analyzed by fragment analysis, in a 96-well plate. The reaction contained 1 µl of PCR products, 0.5 µl of GeneScan™ 600 LIZ™ Dye Size Standard (Thermo scientific, US), for a total volume of 10 µl. The genotypes were determined by a Fragment analyzer, ABI 3130 (Thermo scientific, US). The fluorescence of each well was analyzed automatically by Applied Biosystems software v2.2.2 (Thermo scientific, US).

CD44 rs187116, and CD133 rs3130 were analyzed by polymerase chain reaction -restriction fragment length polymorphism (PCR-RFLP). DNA templates were amplified with primers, as shown in Table 1. Afterwards, the PCR products were cut by restriction enzymes. The enzymatic digestion followed the manufacturer’s protocol, and the fragments were analyzed by using 2% agarose gel electrophoresis.

CD44 rs13347, CD44 rs4756196, CD133 rs2240688, and FOXO3 rs2802292 were analyzed by TaqMan SNP Genotyping (Thermo scientific, US). Each reaction contained DNA template (2 – 5 ng/µl), 2X HS Taq Master Mix (Bioline, Canada), 40X TaqMan probe and primers, and sterile water. The conditions of the manufacturer’s procedure were carefully observed.

Statistical Analysis

The association between the genetic variations and the risk of breast cancer, was calculated by using MedCalc’s odds ratio calculator online software (https://www.medcalc.org/calc/oddsratio.php) giving an odds ratio (OR), 95% confidence interval (95% CI), and P – value at the significant level p < 0.05. Hardy-Weinberg equilibrium (HWE) analysis of 15 polymorphic loci was performed by using online calculator (http://www.oeye.org/software/hwe-mr-calc.shtml) (Rodriguez et al., 2009) and simple calculator of Hardy-Weinberg equilibrium from Laboratory of Immunogenomics and Immunoproteomics, Department of Pathological Physiology, Faculty of Medicine and Dentistry, Palacky University, Czech Republic (http://www.dr-petrek.eu/documents/HWE.xls).

Results

Among the 12 genes studied, 15 polymorphic loci were genotyped to attempt to establish breast cancer biomarkers in the Thai population. The results showed that CD44 rs187116 (c.67+4838G>A), CD133 rs2240688 (c.*667A>C), NF-kB1 rs28362491, and GSTM1 were associated with the risk of breast cancer (Table 2).
Table 1. Genotyping Methods, Primer Sequences, and Product Size of the Genes

| Genes          | Genotyping methods | Primer sequence (5'→3')                                                                 | PCR product (bp)       | Reference                        |
|----------------|--------------------|----------------------------------------------------------------------------------------|------------------------|----------------------------------|
| ALDH1A1        | Fragment analysis  | F: 5′ 6 FAM - GCACCTGAAAATACACAAAGACTGAT 3′ R: 5′ AGAATAAGTTAGAGGAGTTGGAAGGTGCTT 3′ | HWT 213 HDA 196        | Spence et al., 2003              |
|                |                    | F: 5′ 6 FAM - AACGCTGAAAATACACAAAGACTGAT 3′ R: 5′ AGAATAAGTTAGAGGAGTTGGAAGGTGCTT 3′ | HET 213, 196           |                                   |
| Caspase 8      | Fragment analysis  | F: 5′ 6 FAM - AACTTGCCAAGGTCGCTGCG 3′ R: 5′ TGGAGCTGCTTCCGTCTCT 3′                  | HDL 96 HDA 103         | Kuhlmann et al., 2016            |
| (rs834129)     |                    | F: 5′ 6 FAM - AACTTGCCAAGGTCGCTGCG 3′ R: 5′ TGGAGCTGCTTCCGTCTCT 3′                  | HET 103, 96            |                                   |
| Caspase 9      | Fragment analysis  | F: 5′ 6 FAM - CGTTGGAGATGCGTCCTGCG 3′ R: 5′ CGGCTTCCAGGACGACCCTCCT 3′              | HDL 237 HDA 257        | Park et al., 2006                |
| (rs4645982)    |                    | F: 5′ 6 FAM - CGTTGGAGATGCGTCCTGCG 3′ R: 5′ CGGCTTCCAGGACGACCCTCCT 3′              | HET 257, 237           |                                   |
| CD44 rs187116  | PCR - RFLP (MsiI*) | F: 5′ CTTCGCGAAGAGAAGACCTTCCC 3′ R: 5′ AGGGTTGTTGAGATCACCTG 3′                  | HWT 93, 60 HVA 153     | Winder et al., 2011              |
|                |                    |                                                                                        | HET 153, 93, 60        |                                   |
| CD44 rs13347   | TaqMan probe      | Commercial kit                                                                       |                        | Thermo scientific, US            |
| CT-T           |                    |                                                                                        |                        |                                   |
| CD44 rs4756196 | TaqMan probe      | Commercial kit                                                                       |                        | Thermo scientific, US            |
| A-G            |                    |                                                                                        |                        |                                   |
| CD133 rs3130   | PCR - RFLP (EcoRI*) | F: 5′ GTGCGGTGATCAGTTACCAAGGA 3′ R: 5′ ACCTGCGTAACTCCATCTGA 3′ | HWT 527 HDA 404, 120  | this study                        |
| T-C            |                    |                                                                                        | HDA 524, 404, 120      |                                   |
| CD133 rs2240688| TaqMan probe      | Commercial kit                                                                       |                        | Thermo scientific, US            |
| A-C            |                    |                                                                                        |                        |                                   |
| FOXO3 rs8200292| TaqMan probe      | Commercial kit                                                                       |                        | Thermo scientific, US            |
| T-G            |                    |                                                                                        |                        |                                   |
| GSTM1          | PCR                | F: 5′ GGGGCTGCAATAATATACGTTTG 3′ R: 5′ GAATCCCTGGAAGAGTCAAAAGGC 3′ | Present 215            | Hezova et al., 2012              |
|                |                    |                                                                                        | Absent Null            |                                   |
| GSTT1          | PCR                | F: 5′ TTCTTATTGTTCTTCTCATACTCC 3′ R: 5′ TACGCCGATATCGGCCAGAGCA 3′ | Present 480            |                                   |
|                |                    |                                                                                        | Absent Null            |                                   |
| NF-κB1         | rs28362491         | Fragment analysis                                                                     | HWT 281 HDA 277        | Gautam et al., 2017              |
|                |                    | F: 5′ 6 FAM - TGGGGCAAAATGCTTATGTA 3′ R: 5′ CTGGAGCCGGCATTGAGAAGG 3′               | HWT 281, 277           |                                   |
| MDMP SNP309    | rs2279744 A-C      | ARMS - PCR                                                                            | HWT 224, 122           | Zhang et al., 2006               |
| T-G            |                    | R1: 5′ TGCCCACTGACACGGCCCAATGGCCTCCAG 3′ F1: 5′ GGCGCCCGGGGGGCCTCGGGGGCTT 3′       | HIR 224, 158           |                                   |
|                |                    | R2: 5′ TGCCCACTGACACGGCCCAATGGCCTCCAG 3′ F2: 5′ GGCGCCCGGGGGGCCTCGGGGGCTT 3′       | HIR 224, 158           |                                   |
| TGFβ2          | Fragment analysis  | F: 5′ 6 FAM - GAAGCTGTTGATATGATCTAGCA 3′ R: 5′ CGGCCCTGACACAGTTGATTTA 3′         | HWT 146 HDA 142        | Beissner et al., 2006            |
|                |                    | R: 5′ CGGCCCTGACACAGTTGATTTA 3′                                                      | HWT 146, 142           |                                   |
| VEGF           | rs35569394         | Fragment analysis                                                                     | HWT 185 HDA 168        | Rezaei et al., 2016              |
|                |                    | F: 5′ 6 FAM - AGATCTGTTGATATGATCTAGCA 3′ R: 5′ GAACCTTCCGCACCTGCAGTTG 3′         | HWT 185, 168           |                                   |
|                |                    |                                                                                        | Absent Null            |                                   |

*Restriction enzyme; HWT, Homozygous wildtype; HVA, Homozygous variant; HET, Heterozygous; HDL, Homozygous deletion; HIS, Homozygous insertion

CD44 rs187116, the homozygous variant (AA) was significantly associated with an increased risk (OR = 2.03; 95% CI: 1.02 to 4.02; p = 0.041) when compared to the homozygous wildtype (GG). Significant association of CD133 rs2240688 was found only in C allele (OR = 1.46; 95% CI: 1.03 to 2.07; p = 0.032), but also in the recessive model (CC + AC) (OR = 1.57; 95% CI: 1.03 to 2.41; p = 0.034). The 4- base pair deletion of NF-κB1 rs28362491 and the homozygous null allele of GSTM1 were associated with increased risk of breast cancer. According to NF-κB1, the odds ratio of the homozygous deletion (*2*2 genotype) was 1.95 (95% CI: 1.02 to 3.72; p = 0.04) and *2 allele was 1.36 (95% CI: 1.00 to 1.84; p = 0.046). For GSTM1, the odds ratio was 1.83 (95% CI: 1.20 to 2.79; p = 0.005). Chi-square (χ²) was used to analyze HWE. The results showed that the observed genotype frequencies of each locus did not significantly deviate from their expected frequencies, indicating that the population of this study is of infinitely large size and in accordance with an ideal population in Hardy-Weinberg. The HWE of the detoxification genes could not be calculated (Table 2).

Four significant associated loci, CD44 rs187116G, CD133 rs2240688A, NF-κB1 rs28362491, and GSTM1, were combined to obtain the candidate genotypes that tended to be associated with a risk for breast cancer. As shown in Table 3, the AA-CC-*1*2- homozygous null allele combination showed the most significant association with an increased risk of breast cancer (OR = 21.00; 95% CI: 1.77 to 248.11; p = 0.015), followed by GA- AA-*2*-homozygous null allele (OR = 9.00; 95% CI: 1.14 to 71.04; p = 0.037) and GG-AC-*1*2- homozygous null allele (OR = 8.00; 95% CI: 1.24 to 51.50; p = 0.028). The variant genotype, AA-CC-*2*2- homozygous null allele, was not found in this combination.

**Discussion**

Breast cancer biomarkers play an important role in predicting the progression of tumors, effective treatments, and risk assessments. Mutation of some genes, including BRCA1, BRCA2, CD44 and CD133 are said to be associated with an increased risk of breast cancer (Tulsyan et al., 2013; Mehrgou and Akouchekian., 2016), but the association of these genes with disease has not been comprehensively investigated in a Thai population.

Twelve genes, 15 loci were divided into 7 groups of genes that relate to hallmarks of cancer. The group of detoxification genes (GSTM1 and GSTT1) and an inflammatory gene (NF-κB1) are related to tumor-promoting inflammation, while the growth factor genes (TGFβ2 and VEGF) are related to inducing angiogenesis and sustaining proliferative signaling. The
Table 2. Associations between the Groups of Interested Genes and the Risk of Breast Cancer

| Genes         | Total (n = 360) n, (%) | Patients (n = 184) n, (%) | Controls (n = 176) n, (%) | Odds ratio (95% CI) | P - value (<0.05) |
|---------------|------------------------|---------------------------|---------------------------|---------------------|------------------|
| **Cancer stem cell marker genes** |                        |                           |                           |                     |                  |
| CD44          |                        |                           |                           |                     |                  |
| rs187116 G>A  |                        |                           |                           |                     |                  |
| Genotypes     |                        |                           |                           |                     |                  |
| GG            | 141 (39.17)            | 71 (38.59)                | 70 (39.77)                | 1.00 (reference)    |                  |
| GA            | 170 (47.22)            | 80 (43.48)                | 90 (51.14)                | 0.87 (0.56 to 1.37) | 0.562            |
| AA            | 49 (13.61)             | 33 (17.93)                | 16 (9.09)                 | 2.03 (1.02 to 4.02) | 0.041#           |
| AA + GA       | 219 (60.83)            | 113 (61.41)               | 106 (60.23)               | 1.05 (0.68 to 1.60) | 0.817            |
| Alleles       |                        |                           |                           |                     |                  |
| G             | 452 (62.78)            | 222 (60.33)               | 230 (65.34)               | 1.00 (reference)    |                  |
| A             | 268 (37.22)            | 146 (39.67)               | 122 (34.66)               | 1.23 (0.91 to 1.67) | 0.164            |
| HWE χ² = 0.04, p = 0.84 |        |                           |                           |                     |                  |
| rs13347 C>T   |                        |                           |                           |                     |                  |
| Genotypes     |                        |                           |                           |                     |                  |
| CC            | 157 (43.61)            | 82 (44.56)                | 75 (42.61)                | 1.00 (reference)    |                  |
| CT            | 162 (45.00)            | 83 (45.11)                | 79 (44.89)                | 0.96 (0.61 to 1.49) | 0.858            |
| TT            | 41 (11.39)             | 19 (10.33)                | 22 (12.50)                | 0.78 (0.39 to 1.57) | 0.502            |
| TT + CT       | 203 (56.39)            | 102 (55.34)               | 101 (57.39)               | 0.92 (0.60 to 1.40) | 0.709            |
| Alleles       |                        |                           |                           |                     |                  |
| C             | 476 (66.11)            | 247 (67.12)               | 229 (65.06)               | 1.00 (reference)    |                  |
| T             | 244 (33.89)            | 121 (32.88)               | 123 (34.94)               | 0.91 (0.66 to 1.24) | 0.558            |
| HWE χ² = 0.01, p = 0.94 |        |                           |                           |                     |                  |
| rs4756196 A>G |                        |                           |                           |                     |                  |
| Genotypes     |                        |                           |                           |                     |                  |
| AA            | 179 (49.72)            | 84 (45.65)                | 95 (53.98)                | 1.00 (reference)    |                  |
| AG            | 150 (41.67)            | 81 (44.02)                | 69 (39.20)                | 1.32 (0.85 to 2.05) | 0.201            |
| GG            | 31 (8.61)              | 19 (10.33)                | 12 (6.82)                 | 1.79 (0.82 to 3.90) | 0.143            |
| GG + AG       | 181 (50.28)            | 100 (54.35)               | 81 (46.02)                | 1.39 (0.92 to 2.11) | 0.114            |
| Alleles       |                        |                           |                           |                     |                  |
| A             | 508 (70.56)            | 249 (67.66)               | 259 (73.58)               | 1.00 (reference)    |                  |
| G             | 212 (29.44)            | 119 (32.34)               | 93 (26.42)                | 1.33 (0.96 to 1.83) | 0.082            |
| HWE χ² = 0.00, p = 0.96 |        |                           |                           |                     |                  |
| rs31310 T>C   |                        |                           |                           |                     |                  |
| Genotypes     |                        |                           |                           |                     |                  |
| TT            | 35 (9.72)              | 13 (7.07)                 | 22 (12.50)                | 1.00 (reference)    |                  |
| TC            | 143 (39.72)            | 71 (38.58)                | 72 (40.91)                | 1.66 (0.78 to 3.56) | 0.186            |
| CC            | 182 (50.56)            | 100 (54.35)               | 82 (46.59)                | 2.06 (0.97 to 4.34) | 0.056            |
| CC + TC       | 325 (90.28)            | 171 (92.93)               | 154 (87.50)               | 1.87 (0.91 to 3.85) | 0.085            |
| Alleles       |                        |                           |                           |                     |                  |
| T             | 213 (29.58)            | 97 (26.36)                | 116 (32.95)               | 1.00 (reference)    |                  |
| C             | 507 (70.42)            | 271 (73.64)               | 236 (67.05)               | 1.37 (0.99 to 1.89) | 0.052            |
| HWE χ² = 0.78, p = 0.38 |        |                           |                           |                     |                  |
| rs2240688 A>C |                        |                           |                           |                     |                  |
| Genotypes     |                        |                           |                           |                     |                  |
| AA            | 213 (59.17)            | 99 (53.80)                | 114 (64.77)               | 1.00 (reference)    |                  |
| AC            | 126 (35.00)            | 72 (39.13)                | 54 (30.68)                | 1.53 (0.98 to 2.39) | 0.058            |
| CC            | 21 (5.83)              | 13 (7.07)                 | 8 (4.55)                  | 1.87 (0.74 to 4.70) | 0.182            |
| CC + AC       | 147 (40.83)            | 85 (46.20)                | 62 (35.23)                | 1.57 (1.03 to 2.41) | 0.034#           |
| Alleles       |                        |                           |                           |                     |                  |
| A             | 552 (76.67)            | 270 (73.37)               | 282 (80.11)               | 1.00 (reference)    |                  |
| C             | 168 (23.33)            | 98 (26.63)                | 70 (19.89)                | 1.46 (1.03 to 2.07) | 0.032#           |
Table 2. Continued

| Genes                  | Total (n = 360) | Patients (n = 184) | Controls (n = 176) | Odds ratio (95% CI) | P - value (<0.05) |
|------------------------|-----------------|-------------------|-------------------|---------------------|------------------|
| Genes                  | n, (%)          | n, (%)            | n, (%)            |                     |                  |
| **HWE χ² = 0.17, p = 0.68** |                 |                    |                   |                     |                  |
| **ALDH1A1 (17 bp Del)**|                 |                    |                   |                     |                  |
| Genotypes              |                 |                    |                   |                     |                  |
| *1*1                   | 329 (91.39)     | 173 (94.03)        | 156 (88.64)       | 1.00 (reference)    |                  |
| *1*2                   | 29 (8.06)       | 10 (5.43)          | 19 (10.80)        | 0.47 (0.21 to 1.05) | 0.066            |
| *2*2                   | 2 (0.55)        | 1 (0.54)           | 1 (0.56)          | 0.90 (0.05 to 14.53)| 0.941            |
| *2*2 + *1*2            | 31 (8.61)       | 11 (5.97)          | 20 (11.36)        | 0.49 (0.23 to 1.06) | 0.073            |
| Alleles                |                 |                    |                   |                     |                  |
| *1                     | 687 (95.42)     | 356 (96.74)        | 331 (94.04)       | 1.00 (reference)    |                  |
| *2                     | 33 (4.58)       | 12 (3.26)          | 21 (5.96)         | 0.53 (0.25 to 1.09) | 0.087            |
| **HWE χ² = 2.25, p = 0.13** |                 |                    |                   |                     |                  |
| **Detoxification genes**|                 |                    |                   |                     |                  |
| **GSTM1**              |                 |                    |                   |                     |                  |
| Present allele         | 151 (41.94)     | 64 (34.78)         | 87 (49.43)        | 1.00 (reference)    |                  |
| Null allele            | 209 (58.06)     | 120 (65.22)        | 89 (50.57)        | 1.83 (1.20 to 2.79) | 0.005#           |
| **HWE (ND)**           |                 |                    |                   |                     |                  |
| **GSTT1**              |                 |                    |                   |                     |                  |
| Present allele         | 230 (63.89)     | 120 (65.22)        | 110 (62.50)       | 1.00 (reference)    |                  |
| Null allele            | 130 (36.11)     | 64 (34.78)         | 66 (37.50)        | 0.88 (0.57 to 1.36) | 0.591            |
| **HWE (ND)**           |                 |                    |                   |                     |                  |
| **Apoptotic genes**    |                 |                    |                   |                     |                  |
| **Caspase 8**          |                 |                    |                   |                     |                  |
| rs3834129 (6 bp InsDel)|                 |                    |                   |                     |                  |
| Genotypes              |                 |                    |                   |                     |                  |
| DelDel                 | 18 (5.00)       | 10 (5.43)          | 8 (4.55)          | 1.00 (reference)    |                  |
| InsDel                 | 118 (32.78)     | 67 (36.42)         | 51 (28.98)        | 1.05 (0.38 to 2.85) | 0.922            |
| InsIns                 | 224 (62.22)     | 107 (58.15)        | 117 (66.57)       | 0.73 (0.27 to 1.92) | 0.526            |
| InsIns + InsDel        | 342 (95.00)     | 174 (94.57)        | 168 (95.45)       | 0.82 (0.31 to 2.15) | 0.699            |
| Alleles                |                 |                    |                   |                     |                  |
| Del                    | 154 (21.39)     | 87 (23.64)         | 67 (19.03)        | 1.00 (reference)    |                  |
| Ins                    | 566 (78.61)     | 281 (76.36)        | 285 (80.97)       | 0.75 (0.53 to 1.08) | 0.132            |
| **HWE χ² = 0.23, p = 0.63** |                 |                    |                   |                     |                  |
| **Caspase 9**          |                 |                    |                   |                     |                  |
| rs4645982 (20 bp InsDel)|                 |                    |                   |                     |                  |
| Genotypes              |                 |                    |                   |                     |                  |
| DelDel                 | 37 (10.28)      | 20 (10.87)         | 17 (9.66)         | 1.00 (reference)    |                  |
| InsDel                 | 155 (43.06)     | 80 (43.48)         | 75 (42.62)        | 0.90 (0.44 to 1.86) | 0.789            |
| InsIns                 | 168 (46.66)     | 84 (45.65)         | 84 (47.72)        | 0.85 (0.41 to 1.73) | 0.655            |
| InsIns + InsDel        | 323 (89.72)     | 164 (89.13)        | 159 (90.34)       | 0.87 (0.44 to 1.73) | 0.705            |
| Alleles                |                 |                    |                   |                     |                  |
| Del                    | 229 (31.81)     | 120 (32.61)        | 109 (30.97)       | 1.00 (reference)    |                  |
| Ins                    | 491 (68.19)     | 248 (67.39)        | 243 (69.03)       | 0.92 (0.67 to 1.26) | 0.636            |
| **HWE χ² = 0.02, p = 0.89** |                 |                    |                   |                     |                  |
| **Inflammatory genes** |                 |                    |                   |                     |                  |
| **NF-κB1**             |                 |                    |                   |                     |                  |
| rs28362491 (4 bp Del)  |                 |                    |                   |                     |                  |
| Genotypes              |                 |                    |                   |                     |                  |
| *1*1                   | 142 (39.44)     | 66 (35.87)         | 76 (43.18)        | 1.00 (reference)    |                  |
| *1*2                   | 164 (45.56)     | 84 (45.65)         | 80 (45.46)        | 1.20 (0.77 to 1.89) | 0.408            |
| *2*2                   | 54 (15.00)      | 34 (18.48)         | 20 (11.36)        | 1.95 (1.02 to 3.72) | 0.04#             |
| *2*2 + *1*2            | 218 (60.56)     | 118 (64.13)        | 100 (56.82)       | 1.35 (0.88 to 2.07) | 0.156            |
| Genes                  | Total (n = 360) n, (%) | Patients (n = 184) n, (%) | Controls (n = 176) n, (%) | Odds ratio (95% CI) | P - value (<0.05) |
|------------------------|------------------------|---------------------------|---------------------------|---------------------|-------------------|
| Alleles                |                        |                           |                           |                     |                   |
| *1                     | 448 (62.22)            | 216 (58.69)               | 232 (65.91)               | 1.00 (reference)    |                   |
| *2                     | 272 (37.78)            | 152 (41.31)               | 120 (34.09)               | 1.36 (1.00 to 1.84) | 0.046#            |
| HWE χ² = 0.35, p = 0.56|                        |                           |                           |                     |                   |
| Growth factor genes    |                        |                           |                           |                     |                   |
| TGFβ2 (4 bp Del)       |                        |                           |                           |                     |                   |
| Genotypes              |                        |                           |                           |                     |                   |
| *1*1                   | 11 (3.06)              | 3 (1.63)                  | 8 (4.55)                  | 1.00 (reference)    |                   |
| *1*2                   | 99 (27.50)             | 50 (27.17)                | 49 (27.84)                | 2.72 (0.68 to 10.86) | 0.156             |
| *2*2                   | 250 (69.44)            | 131 (71.20)               | 119 (67.61)               | 2.93 (0.76 to 11.32) | 0.117             |
| *2*2 + *1*2            | 349 (96.94)            | 181 (98.37)               | 168 (95.45)               | 2.87 (0.74 to 11.01) | 0.123             |
| Alleles                |                        |                           |                           |                     |                   |
| *1                     | 121 (16.81)            | 56 (15.22)                | 65 (18.47)                | 1.00 (reference)    |                   |
| *2                     | 599 (83.19)            | 312 (84.78)               | 287 (81.53)               | 1.26 (0.85 to 1.86) | 0.244             |
| HWE χ² = 0.10, p = 0.75|                        |                           |                           |                     |                   |
| VEGF                   |                        |                           |                           |                     |                   |
| rs35569394 (18 bp Del) |                        |                           |                           |                     |                   |
| Genotypes              |                        |                           |                           |                     |                   |
| *1*1                   | 29 (8.06)              | 15 (8.15)                 | 14 (7.95)                 | 1.00 (reference)    |                   |
| *1*2                   | 145 (40.28)            | 77 (41.85)                | 68 (38.64)                | 1.05 (0.47 to 2.34) | 0.892             |
| *2*2                   | 186 (51.67)            | 92 (50.00)                | 94 (53.41)                | 0.91 (0.41 to 1.99) | 0.82              |
| *2*2 + *1*2            | 331 (91.94)            | 169 (91.85)               | 162 (92.05)               | 0.97 (0.45 to 2.08) | 0.945             |
| Alleles                |                        |                           |                           |                     |                   |
| *1                     | 203 (28.19)            | 107 (29.08)               | 96 (27.27)                | 1.00 (reference)    |                   |
| *2                     | 517 (71.81)            | 261 (70.92)               | 256 (72.73)               | 0.91 (0.66 to 1.26) | 0.59              |
| HWE χ² = 0.01, p = 0.92|                        |                           |                           |                     |                   |
| Proto-oncogene         |                        |                           |                           |                     |                   |
| MDM2 SNP309            |                        |                           |                           |                     |                   |
| rs2279744 T>G          |                        |                           |                           |                     |                   |
| Genotypes              |                        |                           |                           |                     |                   |
| TT                     | 81 (22.50)             | 46 (25.00)                | 35 (19.89)                | 1.00 (reference)    |                   |
| GT                     | 193 (53.61)            | 95 (51.63)                | 98 (55.68)                | 0.73 (0.43 to 1.24) | 0.253             |
| GG                     | 86 (23.89)             | 43 (23.37)                | 43 (24.43)                | 0.76 (0.41 to 1.40) | 0.379             |
| GG + GT                | 279 (77.50)            | 138 (75.00)               | 141 (80.11)               | 0.74 (0.45 to 1.22) | 0.246             |
| Alleles                |                        |                           |                           |                     |                   |
| T                      | 355 (49.31)            | 187 (50.82)               | 168 (47.73)               | 1.00 (reference)    |                   |
| G                      | 365 (50.69)            | 181 (49.18)               | 184 (52.27)               | 0.88 (0.65 to 1.18) | 0.407             |
| HWE χ² = 1.89, p = 0.17|                        |                           |                           |                     |                   |
| Tumor suppressor genes |                        |                           |                           |                     |                   |
| FOXO3                  |                        |                           |                           |                     |                   |
| rs2802292 T>G          |                        |                           |                           |                     |                   |
| Genotypes              |                        |                           |                           |                     |                   |
| TT                     | 167 (46.39)            | 90 (48.92)                | 77 (43.75)                | 1.00 (reference)    |                   |
| GT                     | 154 (42.78)            | 79 (42.93)                | 75 (42.61)                | 0.90 (0.58 to 1.39) | 0.642             |
| GG                     | 39 (10.83)             | 15 (8.15)                 | 24 (13.64)                | 0.53 (0.26 to 1.09) | 0.085             |
| GG + GT                | 193 (53.61)            | 94 (51.08)                | 99 (56.25)                | 0.81 (0.53 to 1.23) | 0.326             |
| Alleles                |                        |                           |                           |                     |                   |
| T                      | 488 (67.78)            | 259 (70.38)               | 229 (65.06)               | 1.00 (reference)    |                   |
| G                      | 232 (32.22)            | 109 (29.62)               | 123 (34.94)               | 0.78 (0.57 to 1.07) | 0.126             |
| HWE χ² = 0.15, p = 0.70|                        |                           |                           |                     |                   |

# significant level at p < 0.05; ND, no data
Table 3. The Combined Genotypes of Genes that were Significant in Increasing the Risk of Breast Cancer

| Genotypes combination | CD133 rs187116 | NF-κB1 | GSTM1 | Patients (n = 184) n, (%) | Controls (n = 176) n, (%) | OR (95% CI) | P - value (p < 0.05) |
|-----------------------|-----------------|--------|--------|--------------------------|--------------------------|-------------|----------------------|
| GG                    | AA              | *1*1   | present allele | 3 (1.63) | 9 (5.11) | 1.00 (reference) |                     |
| GG                    | AC              | *1*2   | null allele | 8 (4.34) | 3 (1.70) | 8.00 (1.24 to 51.50) | 0.028*          |
| GA                    | AA              | *2*2   | null allele | 6 (3.26) | 2 (1.13) | 9.00 (1.14 to 71.04) | 0.037*          |
| AA                    | AA              | *1*1   | null allele | 7 (3.80) | 1 (0.56) | 21.00 (1.77 to 248.11) | 0.015*          |
| AA                    | CC              | *2*2   | null allele | ND       | ND      | ND                   | ND               |

USA, Significant value at p < 0.05; *1 wildtype, *2 deletion

Tumor suppressor gene (FOXO3) and proto-oncogene (MDM2) are involved in evading growth suppressors, and the apoptotic genes (caspase 8 and caspase 9) relate to resisting cell death. Moreover, the variation of cancer stem cell marker genes (CD44 rs187116, CD44 rs13347, CD44 rs4756196, CD133 rs5130, CD133 rs2240688, and ALDH1A1), were reported to be associated with an increasing cancer risk (Winder et al., 2011; Jiang et al., 2012; Liu et al., 2016; 2017; Lin et al., 2018). The results of this study showed that CD44 rs187116 and CD133 rs2240688 of cancer stem cell marker genes, the inflammatory gene, NF-κB1, and the detoxification gene, GSTM1 were significantly associated with an increased risk of breast cancer (p = 0.041, p = 0.033, p = 0.046, and p = 0.005, respectively).

Cancer stem cells are important in tumor progression, spreading, and in resistance to conventional therapy for breast cancer (Sin and Lim, 2017). Biomarkers, such as CD24, CD44, CD133, and ALDH1, are mostly used to identify CSC in the tumors (Medema, 2013). Previous reports showed that the expression of these biomolecules might increase in CSC (Sheridan et al., 2006; Glumac and Le Beau, 2018). The variation of these biomarker genes was also associated with the risk of cancer (Jiang et al., 2012; Jia et al., 2017). Hence, the variations of CSC biomarker genes might relate to risk of cancer. Our study found that the AA genotype of CD44 rs187116 (c.67+4883G>A) increased the risk of breast cancer compared with wildtype genotype (OR: 2.03; 95% CI: 1.02–4.02; p = 0.041). In contrast, previous studies of rs187116 variation reported that patients with at least one G allele, had an increased risk and recurrence of cancer after gastric surgery in Iran, Japan, North America, and Northeast Thailand (Winder et al., 2011; Bitaraf et al., 2015; Suenaga et al., 2015; Tongtawee et al., 2017). Our study of CD133, rs22406882 (c.*667A>C) shows that the C allele tended to increase the risk of cancer (OR: 1.46; 95% CI: 1.03–2.07; p = 0.033), which is consistent with previous reports that the AC or CC genotypes were associated with increased risk and reduced overall survival rate in lung cancer patients in China (Liu et al., 2016; 2017). However, the variant AC/CC genotypes were associated with decreased risk of gastric cancer (OR: 0.81; 95% CI: 0.67–0.97; p = 0.023) (Jia et al., 2017). Many studies report that ALDH1 correlated with cell migration, tumor metastasis, and poor prognosis of breast cancer (Ginestier et al., 2007; Tan et al., 2013; Li et al., 2017), but our study found no such association.

The NF-κB is a main regulator of inflammation, cancer development, immune response, and apoptosis (Chen et al., 2018b; Zhou et al., 2009), and several genetic variations are associated with the risk of oral, esophageal, gastric, and colorectal cancers (Lo et al., 2009; Umar et al., 2013; Song et al., 2013; Chen et al., 2018b). The 4-bp ATTG deletion in the promotor of NF-κB1 rs28362491 resulted in the loss of binding to nuclear proteins that reduced promotor activity, hence decreased NF-κB1 transcription, and protein production (Karban et al., 2004; Zhou et al., 2009). This study showed that the *2*2 homozygous genotype (del/del) was associated with a 2–fold increased risk (p = 0.041) and with the *2* allele was 1.36 increased risk (p = 0.046). This finding is consistent with a previous report that this polymorphism was not only associated with the risk of oral cancer (Chen et al., 2018b), but also with the development of gastric cancer and colorectal cancer (Cavalcante et al., 2017).

GSTM1, one of the glutathione-S-transferase gene family, produces the GSTM1 enzyme involved in the detoxification of polycyclic aromatic hydrocarbons and other carcinogens (Strange and Fryer, 1999). The homozygous null allele genotype increase damage to DNA caused by these agents and this genotype is a risk factor for breast cancer (Strange and Fryer, 1999; de Aguiar et al., 2012; Chirillà et al., 2014). In this study, the homozygous null allele genotype was associated with an increased risk of breast cancer (OR: 1.83; 95% CI: 1.20–2.79; p = 0.005). It was found in 65.22% in patients, similarly to other studies that found it in over 50% (Possuelo et al., 2013; Chirillà et al., 2014).

The other polymorphisms including detoxification genes (GSTT1), cancer stem cell marker genes (CD44 rs13347, CD44 rs4756196, CD133 rs5130, and ALDH1A1), apoptotic genes (caspase 8 and caspase 9), growth factor genes (TGFβ2 and VEGF), tumor suppressor gene (FOXO3), and proto-oncogene (MDM2) did not show an association with breast cancer in this study, indicating that these polymorphisms do not necessarily increase the risk of breast cancer in our population. However, these genes were reported to be associated with other cancers, such as nasopharyngeal, gastric, lung, and colorectal cancer (Son et al., 2006; Xiao et al., 2013; Aravantinos et al., 2015; Jia et al., 2017). The genetic background of the population might be the cause of this discrepancy.

We combined the four significant associated polymorphic loci, including CD44 rs187116, CD133 rs2240688, NF-κB1 rs28362491 and GSTM1, and we enquired as to which marker combinations might increase the risk for breast cancer. The results showed that the

DOI:10.31557/APJCP.2019.20.8.2493

Asian Pacific Journal of Cancer Prevention, Vol 20

2499
The biological functions of the 4 selected genes have been previously described. The CD44 rs1871116 associated with a higher expression of CD44 protein in carcinogenesis, is involved in cancer progression and cancer cell metabolism (Chen et al., 2018a). The functions of CD133 rs2240688 are not fully understood; it has been identified as the transcription factor binding site relating to the tumor initiation, maintenance and metastasis (Cheng et al., 2013). For NF-kB1, 4 bp deletion in the promoter affected to reduce the response of cells to inflammation (Karban et al., 2004; Zhou et al., 2009). The deletion of GSTM1 affected the detoxification of the cells by reducing the function of glutathione S transferase, leading to accumulation of the carcinogens within the cells (Strange and Fryer, 1999).

This study showed that the gene combination of CD44 rs1871116, CD133 rs2240688, GSTM1 and NF-kB1 rs28362491 could act as a new genetic biomarker to predict the risk of breast cancer in a Thai population and it could benefit cancer surveillance. However, among 360 samples in this study, the demographic and clinical characteristics of breast cancer patients and controls were not available due to the limitations in the data retrieval from medical records and histopathologic reports. For the further study, authors suggest the larger sample sizes with more information on demographic and clinical characteristics of participants must be obtained to provide more comprehensive and accurately representative results.

Acknowledgements

Authors would like to thank all volunteers who donated blood samples. This work was partially supported by funding from National Research Council of Thailand (NRCT) 2019 via Naresuan University No. 2562/8. MS was supported by Naresuan University via IRU project and the grant Number R2562B085. Many thanks go to Prof. Jorge H. Aigla of Faculty of Medical Science, Naresuan University for his editing assistance and advice on English expression in this document.

References

Al-Hajj M, Whica MS, Benito-Hernandez A, Morrison SJ, Clarke MF (2003). Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A, 100, 3983-8.
Aravantinos G, Isakidou A, Karantanos T, et al (2015). Association of CD133 polymorphisms and response to bevacizumab in patients with metastatic colorectal cancer. Cancer Biomark, 15, 843-50.
Ayob AZ, Ramsammy TS (2018). Cancer stem cells as key drivers of tumour progression. J Biomed Sci, 25, 20-38.
Beisner J, Buck MB, Fritz P, et al (2006). A novel functional polymorphism in the transforming growth factor-β2 gene promoter and tumor progression in breast cancer. Cancer Res, 66, 7554-61.
Bitaraf SM, Mahmoudian RA, Abbaszadegan M, et al (2018). Association of two CD44 polymorphisms with clinical outcomes of gastric cancer patients. Asian Pac J Cancer Prev, 19, 1313-8.
Bozorgi A, Khazaei M, Khazaei MR (2015). New findings on breast cancer stem cells: A review. J Breast Cancer, 18, 303-12.
Bray F, Ferlay J, Soerjomataram I, et al (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 68, 394-424.
Carmeliet P (2005). VEGF as a key mediator of angiogenesis in cancer. Oncology, 69, 4-10.
Cavalcante GC, Amador MA, Ribeiro Dos Santos AM, et al (2017). Analysis of 12 variants in the development of gastric and colorectal cancers. World J Gastroenterol, 23, 8533–43.
Chen C, Zhao S, Karnad A, et al (2018a). The biology and role of CD44 in cancer progression: therapeutic implications. J Hematol Oncol, 11, 64-87.
Chen F, Liu F, Yan L, et al (2018b). A functional haplotype of NFKB1 influence susceptibility to oral cancer: a population-based and in vitro study. Cancer Med, 7, 2211-18.
Cheng M, Yang L, Yang R, et al (2013). A microRNA-135a/b binding polymorphism in CD133 confers decreased risk and favorable prognosis of lung cancer in Chinese by reducing CD133 expression. Carcinogenesis, 34, 2292-99.
Chirilă DN, Bălăcescu O, Popp R, et al (2014). GSTM1, GSTT1 and GSTP1 in patients with multiple breast cancers and breast cancer in association with another type of cancer. Chirurgia (Bucur), 109, 626-33.
de Aguiar ES, Giacomazzi J, Schmidt AV, et al (2012). GSTM1, GSTT1, and GSTP1 polymorphisms, breast cancer risk factors and mammographic density in women submitted to breast cancer screening. Rev Bras Epidemiol, 15, 246-55.
Deng N, Zhou H, Fan H, Yuan Y (2017). Single nucleotide polymorphisms and cancer susceptibility. Oncotarget, 8, 110635-49.
Duffy MJ, Harbeck N, Nap M (2017). Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM). Eur J Cancer, 75, 284-98.
Eskandari-Nasab E, Hashemi M, Ebrahimii M, Amininia S (2016). The functional 4-bp insertion/deletion ATTG polymorphism in the promoter region of NF-KB1 reduces the risk of BC. Cancer Biomark, 16, 109-15.
Espin-Palazón R, Traver D (2016). The NF-kB family: Key players during embryonic development and HSC emergence. Exp Hematol, 44, 519-27.
Essaghir A, Dif N, Marbehant CY, et al (2009). The transcription of FOXO genes is stimulated by FOXO3 and repressed by growth factors. J Biol Chem, 284, 10334-42.
Feng Y, Spezia M, Huang S, et al (2018). Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis. Genes Dis, 5, 77-106.
Gautam A, Gupta S, Mehndiratta M, et al (2017). Association of NFKB1 gene polymorphism (rs28362491) with levels of inflammatory biomarkers and susceptibility to diabetic nephropathy in Asian Indians. World J Diabetes, 8, 66-73.
Ginestier C, Hur MH, Charafe-Jauffret E, et al (2007). ALDH1 is a marker of normal and malignant human mammary stem
cells and a predictor of poor clinical outcome. Cell Stem Cell, 1, 555-67.
Glumac PM, LeBeau AM (2018). The role of CD133 in cancer: a concise review. Clin Transl Med, 7, 18-32.
Hanahan D, Weinberg RA (2011). Hallmarks of cancer: the next generation. Cell, 144, 646-74.
Hezova R, Bienertova-Vasku J, Sachlova M, et al (2012). Common polymorphisms in GSTM1, GSTT1, GSTP1, GSTA1 and susceptibility to colorectal cancer in the Central European population. Eur J Cancer Prev, 17, 17-22.
Hoeben A, Landuyt B, Highley MS, et al (2004). Vascular endothelial growth factor and angiogenesis. Pharmacol Rev, 56, 549-80.
Jia ZF, Wu YH, Cao DH, et al (2017). Polymorphisms of cancer stem cell marker gene CD133 are associated with susceptibility and prognosis of gastric cancer. Future Oncol, 13, 979-89.
Jiang L, Deng J, Zhu X, et al (2012). CD44 rs13347 C>T polymorphism predicts breast cancer risk and prognosis in Chinese populations. Breast Cancer Res, 14, R105.
Karban AS1, Okazaki T, Panhuysen CI, et al (2004). Functional annotation of a novel NFKB1 promoter polymorphism that increases risk for ulcerative colitis. Hum Mol Genet, 13, 35-45.
Kim JH, Park SG, Lee KH, et al (2006). GSTM1 and GSTP1 polymorphisms as potential factors for modifying the effect of smoking on inflammatory response. J Korean Med Sci, 21, 1021-7.
Kuhlmann JD, Bankfalvi A4, Schmid KW, et al (2016). Annotation of a novel NFKB1 promoter polymorphism that predicts breast cancer risk and prognosis in Chinese population. Cancer Genet Cytogenet, 169, 121-7.
Song S, Chen D, Lu J, et al (2011). NFxB1 and NFxB1 polymorphisms are associated with increased risk for sporadic colorectal cancer in a southern Chinese population. PLoS One, 6, e21726.
Soto-Quintana O, Zúñiga-González GM, Ramirez-Patiño R, et al (2015). Association of the GSTM1 null polymorphism with breast cancer in a Mexican population. Genet Mol Res, 14, 13066-75.
Spence JP, Li K, Eriksson CJ, et al (2003). Evaluation of aldehyde dehydrogenase 1 promoter polymorphisms identified in human populations. Alcohol Clin Exp Res, 27, 1389-94.
Strange RC, Fryer AA (1999). The glutathione S-transferases: influence of polymorphism on cancer susceptibility. JARC Sci Publ, 148, 239-49.
Sun YS, Zhao Z, Yang ZN, et al (2017). Breast cancer stem cells-from origins to targeted therapy. Stem Cell Investig, 4, 96-104.
Tan IB, Ngeow J, Tan PH (2013). ALDH1 expression is associated with clinical outcome in a cohort of Chinese non-small cell lung cancer patients. J Surg Oncol, 109, 105-11.
Tongtawee T, Wattanawongdon W, Simawaranon T, et al (2017). Expression of the caspase-8 gene and the risk of lung cancer. Cancer Genet Cytogenet, 505-14.
Tsutsui H, Goto T, Saito M, et al (2012). Potential usefulness of single nucleotide polymorphisms to identify persons at high cancer risk: an evaluation of seven common cancers. J Clin Oncol, 30, 2157-62.
Aoki C, Yamauchi H, Ishimura K, et al (2013). CD44+/CD24- breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis. Breast Cancer Res, 8, R59.
Wang Y, Wang J, Deng Z, et al (2017). Gene combination of CD44, CD133, NF-κB1, and GSTM1 as a risk prediction biomarker of breast cancer. Asian Pacific Journal of Cancer Prevention, Vol 20, 2501.
polymorphisms in breast cancer risk and prognosis: a study in North Indian population. *PLoS One*, 8, e71073.

Umar M, Upadhyay R, Kumar S, Ghoshal UC, Mittal B (2013). Association of common polymorphisms in TNFA, NFkB1 and NFKBIA with risk and prognosis of esophageal squamous cell carcinoma. *PLoS One*, 8, e81999.

Urso L, Calabrese F, Favareto A, Conte P, Pasello G (2016). Critical review about MDM2 in cancer: Possible role in malignant mesothelioma and implications for treatment. *Crit Rev Oncol Hematol*, 97, 220-30.

Villapol S, Logan TT, Symes AJ (2012). Role of TGF-β signaling in neurogenic regions after brain injury. *In tech Open*.

Winder T, Ning Y, Yang D, et al (2011). Germline polymorphisms in genes involved in the CD44 signaling pathway are associated with clinical outcome in localized gastric adenocarcinoma. *Int J Cancer*, 129, 1096-104.

Wu L, Qu X (2015). Cancer biomarker detection: recent achievements and challenges. *Chem Soc Rev*, 44, 2963-97.

Xiao M, Hu S, Zhang L, et al (2013). Polymorphisms of CD44 gene and nasopharyngeal carcinoma susceptibility in a Chinese population. *Mutagenesis*, 28, 577-82.

Xue CX, He XM, Zou DH (2016). Glutathione S-transferase M1 Polymorphism and Breast Cancer Risk: a Meta-Analysis in the Chinese Population. *Clin Lab*, 62, 2277-84.

Zhang X, Miao X, Guo Y, et al (2006). Genetic polymorphisms in cell cycle regulatory genes MDM2 and TP53 are associated with susceptibility to lung cancer. *Hum Mutat*, 27, 110-7.

Zhou B, Rao L, Li Y, et al (2009). A functional insertion/deletion polymorphism in the promoter region of NFKB1 gene increases susceptibility for nasopharyngeal carcinoma. *Cancer Lett*, 275, 72-6.

This work is licensed under a Creative Commons Attribution-Non Commercial 4.0 International License.